| Entry |
|
|---|
| Name |
Ustekinumab (genetical recombination) (JAN);
Ustekinumab (USAN/INN);
Stelara (TN)
|
|---|
| Product |
|
|---|
| Formula |
C6482H10004N1712O2016S46
|
|---|
| Exact mass |
145556.0074
|
|---|
| Mol weight |
145646.04
|
|---|
| Activity |
Treatment of immunologically mediated inflammatory disorders
|
|---|
| Remark |
Therapeutic category: ATC code: |
|---|
| Comment |
Monoclonal antibody
|
|---|
| Target |
|
|---|
| Pathway |
hsa04060 Cytokine-cytokine receptor interaction
hsa04630 Jak-STAT signaling pathway | |
|
|---|
| Interaction |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D09214 Ustekinumab (genetical recombination) (JAN); Ustekinumab (USAN/INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AC Interleukin inhibitors
L04AC05 Ustekinumab
D09214 Ustekinumab (genetical recombination) (JAN); Ustekinumab (USAN/INN)
USP drug classification [BR:br08302]
Dermatological Agents
Dermatological Psoriasis Agents, Systemic
Ustekinumab
D09214 Ustekinumab (genetical recombination) (JAN); Ustekinumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cytokines
Class I cytokines
IL-12 [HSA:3592 3593] [KO:K05406 K05425]
Ustekinumab [ATC:L04AC05]
D09214 Ustekinumab (genetical recombination) (JAN); Ustekinumab (USAN/INN)
IL-23 [HSA:51561] [KO:K05426]
Ustekinumab [ATC:L04AC05]
D09214 Ustekinumab (genetical recombination) (JAN); Ustekinumab (USAN/INN)
 |
|---|
| Other DBs |
|
|---|
